# OnCo record bbi-825 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bbi-825/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bbi-825" ;
  schema:name "BBI-825"@en ;
  schema:description "BBI-825 is an oral small-molecule inhibitor from Boundless Bio that reached phase 1 for solid tumours with resistance gene amplifications; development has stopped."@en ;
  schema:url <https://onco.cc/drugs/bbi-825/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/0001782303/000119312526339093/bold-20260630.htm>, <https://www.sec.gov/Archives/edgar/data/0001782303/000119312526339093/bold-20260630.htm>, <https://clinicaltrials.gov/study/NCT06299761>, <https://clinicaltrials.gov/search?intr=BBI-825> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest", "discontinued" ;
  onco:modality "Oral small-molecule inhibitor" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:companies <https://onco.cc/companies/boundless-bio/> ;
  onco:trials <https://onco.cc/trials/nct06299761/>, <https://onco.cc/trials/nct05827614/> .